Today's Rundown Featured Story | | | Monday, April 27, 2020 Sanofi and Regeneron had high hopes for IL-6 inhibitor Kevzara's chances as a repurposed therapy for COVID-19 patients after anecdotal results in China showed promise. But after an early setback in a U.S. trial, will Kevzara find its footing in phase 3? |
|
|---|
|
Top Stories Monday, April 27, 2020 Japanese Prime Minister Shinzo Abe is set to grant Gilead’s experimental COVID-19 drug remdesivir a special, speedy approval, despite it failing to show any definitive clinical signs that it works. Monday, April 27, 2020 As providers struggle to access critical ventilators to treat patients with COVID-19, UnitedHealth Group and several partners have launched a new, lighter device that can help ease that strain. And they did it in less than 30 days. Monday, April 27, 2020 The leaders of Germany and France and a host of other EU countries and groups have come together with the World Health Organization for an $8 billion push for a new vaccine against COVID-19. Friday, April 24, 2020 Sanofi and Kevzara are downshifting a phase 3 study of IL-6 inhibitor Kevzara to include only the critically ill after early results were less than impressive in severe coronavirus patients. But Roche's rival med scored some early positive data. Meanwhile, Gilead's remdesivir could snag a quick Japan approval. Sunday, April 26, 2020 FierceHealthcare's team recently met — remotely — to talk about some of the biggest shifts in health care and which and what changes might be here to stay. Check it out and let us know what changes you think will stick around. Monday, April 27, 2020 With the spotlight on the global pharmaceutical supply chain, a lockdown at a major Indian manufacturing hub earlier this month caused waves of unrest. Now, weeks later, that hub is back up and running—but concerns about India's control over the U.S. drug supply tap are still alive and well. Friday, April 24, 2020 While hospitals have put elective procedures on pause during the pandemic, patients seeking care for serious health needs have also decreased significantly, new data from Cigna show. Monday, April 27, 2020 Merck & Co. has begun working with the non-profit Institute for Systems Biology and a consortium of companies to investigate the molecular mechanisms behind the novel coronavirus, in a bid to identify new targets for medicines and vaccines. Monday, April 27, 2020 The Trump administration is suspending a program that offered advanced payments to providers and reevaluating another program that offered accelerated payments to health systems after doling out about $100 billion. Monday, April 27, 2020 Members of Congress have called on the FDA to re-evaluate its stance toward COVID-19 antibody tests. Since mid-March, the agency has allowed diagnostic developers to bring their products to market without any outside evaluation that the results they produce are accurate. Monday, April 27, 2020 Tech giant IBM is leveraging its expertise with blockchain technology to help address medical supply chain shortages due to COVID-19. Find out why IBM and other stakeholders believe blockchain technology could be the key to improving the medical supply chain. Monday, April 27, 2020 Bayer enjoyed a better-than-expected first quarter in the early days of COVID-19. But unlike several of its pharma peers that have maintained their forecasts for the full year, the German conglomerate figures uncertainties spawned by the pandemic make quantifying its effects impossible. Monday, April 27, 2020 The FDA granted two emergency authorizations to blood-filtering devices designed to assist the distressed immune and respiratory systems of patients with severe cases of COVID-19. Sunday, April 26, 2020 W2O Group’s latest acquisition adds a health-focused social media analytics firm to the fold. Now operating as W2O Symplur, the new unit digests online conversations and IDs trends among key healthcare voices in real time, giving pharma insights for brand and communication decisions. |
|
.png)
